<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 13 Feb 2021 11:25:50 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>FDA批准第100款抗体药</title><link>https://mp.weixin.qq.com/s/WI7Kk-3pbMKyoVi1967-oQ</link><description></description><content:encoded><![CDATA[FDA批准第100款抗体药]]></content:encoded><pubDate>Sat, 13 Feb 2021 10:07:33 +0800</pubDate></item><item><title>非小细胞肺癌：君实生物PD-1递交新适应症上市申请</title><link>https://mp.weixin.qq.com/s/nlZ0o47Z6pQoFAe7YqYobQ</link><description></description><content:encoded><![CDATA[非小细胞肺癌：君实生物PD-1递交新适应症上市申请]]></content:encoded><pubDate>Thu, 11 Feb 2021 23:40:46 +0800</pubDate></item><item><title>K药头对头：翰思生物PD-1启动非小细胞肺癌2/3期临床</title><link>https://mp.weixin.qq.com/s/WhX4qcDvH00JDRh84jiNVw</link><description></description><content:encoded><![CDATA[K药头对头：翰思生物PD-1启动非小细胞肺癌2/3期临床]]></content:encoded><pubDate>Thu, 11 Feb 2021 23:40:46 +0800</pubDate></item><item><title>创响生物IL-17类抗体申报临床</title><link>https://mp.weixin.qq.com/s/USwtIP2fVGteIfz2mbHbLQ</link><description></description><content:encoded><![CDATA[创响生物IL-17类抗体申报临床]]></content:encoded><pubDate>Thu, 11 Feb 2021 23:40:46 +0800</pubDate></item><item><title>CRISPR：艾伯维3.4亿美元获Caribou技术授权，开发通用CAR-T疗法</title><link>https://mp.weixin.qq.com/s/JaQjqtwbEzdMYgNaITs3cw</link><description></description><content:encoded><![CDATA[CRISPR：艾伯维3.4亿美元获Caribou技术授权，开发通用CAR-T疗法]]></content:encoded><pubDate>Thu, 11 Feb 2021 10:55:01 +0800</pubDate></item><item><title>ADC：Genmab/Seagen向FDA递交Tisotumab Vedotin的上市申请</title><link>https://mp.weixin.qq.com/s/XUyyKl772jc7cB_WfehAFA</link><description></description><content:encoded><![CDATA[ADC：Genmab/Seagen向FDA递交Tisotumab Vedotin的上市申请]]></content:encoded><pubDate>Thu, 11 Feb 2021 10:55:01 +0800</pubDate></item><item><title>新型HER2 ADC：华人科学家研发，对HER2低表达有效</title><link>https://mp.weixin.qq.com/s/TwHUB98zSRYmJWOyu7rWwg</link><description></description><content:encoded><![CDATA[新型HER2 ADC：华人科学家研发，对HER2低表达有效]]></content:encoded><pubDate>Thu, 11 Feb 2021 10:55:01 +0800</pubDate></item><item><title>George Church发明新型AAV载体，降低免疫原性</title><link>https://mp.weixin.qq.com/s/GADhQAcQ2dPDEbW72g0IWA</link><description></description><content:encoded><![CDATA[George Church发明新型AAV载体，降低免疫原性]]></content:encoded><pubDate>Thu, 11 Feb 2021 10:55:01 +0800</pubDate></item><item><title>李氏大药厂PD-L1抗体即将申报上市：</title><link>https://mp.weixin.qq.com/s/0LvVZYZqkIZ0ZcgT8WcE4Q</link><description></description><content:encoded><![CDATA[李氏大药厂PD-L1抗体即将申报上市：]]></content:encoded><pubDate>Wed, 10 Feb 2021 05:37:57 +0800</pubDate></item><item><title>天演药业纳斯达克上市，当天股价大涨58%</title><link>https://mp.weixin.qq.com/s/7AHY4CkET5Of5wrR1rpu1A</link><description></description><content:encoded><![CDATA[天演药业纳斯达克上市，当天股价大涨58%]]></content:encoded><pubDate>Wed, 10 Feb 2021 05:37:57 +0800</pubDate></item><item><title>TCR疗法先驱：Immunocore上市两天市值翻倍，药明等投资</title><link>https://mp.weixin.qq.com/s/YSr3ZZbq_HeJSwUQ7jj6Fg</link><description></description><content:encoded><![CDATA[TCR疗法先驱：Immunocore上市两天市值翻倍，药明等投资]]></content:encoded><pubDate>Wed, 10 Feb 2021 05:37:57 +0800</pubDate></item><item><title>百奥泰终止HER2 ADC临床，已投入研发费用2.26亿元</title><link>https://mp.weixin.qq.com/s/T0SWF17erNP83hrfv3jjCA</link><description></description><content:encoded><![CDATA[百奥泰终止HER2 ADC临床，已投入研发费用2.26亿元]]></content:encoded><pubDate>Tue, 09 Feb 2021 00:06:00 +0800</pubDate></item><item><title>康希诺新冠疫苗有效率65.7%</title><link>https://mp.weixin.qq.com/s/H5WgdUEHX-ErBpLTB80oLQ</link><description></description><content:encoded><![CDATA[康希诺新冠疫苗有效率65.7%]]></content:encoded><pubDate>Tue, 09 Feb 2021 00:06:00 +0800</pubDate></item><item><title>百奥泰HER2 ADC三期临床未达到优效终点</title><link>https://mp.weixin.qq.com/s/j00Rz4veWlk3Lo5pda_9Fg</link><description></description><content:encoded><![CDATA[百奥泰HER2 ADC三期临床未达到优效终点]]></content:encoded><pubDate>Mon, 08 Feb 2021 17:21:26 +0800</pubDate></item><item><title>尚健生物申报PD-L1/CD47双抗</title><link>https://mp.weixin.qq.com/s/cF6jEtAtf6vOv6sFY04Zdw</link><description></description><content:encoded><![CDATA[尚健生物申报PD-L1/CD47双抗]]></content:encoded><pubDate>Mon, 08 Feb 2021 17:21:26 +0800</pubDate></item><item><title>多肽药物研发趋势</title><link>https://mp.weixin.qq.com/s/CxBBXubv5QwRJkftNKwOIw</link><description></description><content:encoded><![CDATA[多肽药物研发趋势]]></content:encoded><pubDate>Sun, 07 Feb 2021 15:17:35 +0800</pubDate></item><item><title>2020年全球畅销药TOP20</title><link>https://mp.weixin.qq.com/s/gFmJ71CV80dpMeJkHv-1qw</link><description></description><content:encoded><![CDATA[2020年全球畅销药TOP20]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>第4款CAR-T疗法：Liso-cel终获FDA批准</title><link>https://mp.weixin.qq.com/s/tjO9AHtzQQz8QuYpZPhTvw</link><description></description><content:encoded><![CDATA[第4款CAR-T疗法：Liso-cel终获FDA批准]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>岸迈生物申报PD-1/LAG-3双抗：EMB-02</title><link>https://mp.weixin.qq.com/s/MMhpsN93Mrw0E_TNtAKVJw</link><description></description><content:encoded><![CDATA[岸迈生物申报PD-1/LAG-3双抗：EMB-02]]></content:encoded><pubDate>Sat, 06 Feb 2021 06:56:31 +0800</pubDate></item><item><title>瑞德西韦销售额28亿美元，支撑吉利德业绩增长10%</title><link>https://mp.weixin.qq.com/s/gsifGUY3-EIECla4SacuwA</link><description></description><content:encoded><![CDATA[瑞德西韦销售额28亿美元，支撑吉利德业绩增长10%]]></content:encoded><pubDate>Fri, 05 Feb 2021 13:58:26 +0800</pubDate></item></channel></rss>